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ABSTRACT

Two vaccinia virus (VACV) expression systems that contain elements from the
lactose (lac) and the tetracycline (tet) operons of E. coli were developed to repress the
expression of a reporter gene, enhanced green fluorescent protein (EGFP), in the presence
of tet operon inducers. In the first system, lac and tet operon elements were arranged in a
gene circuit, and in the presence of increasing concentrations of a lac operon inducer
(isopropyl-β-D-thiogalactoside, IPTG), EGFP expression increased in a dose dependent
manner and at high IPTG concentrations, expression reached the same levels as a positive
control virus. Importantly, in the presence of increasing concentrations of the tet operon
inducer (doxycycline, DOX), EGFP expression decreased in a dose dependent manner
and at high concentrations of DOX, expression was repressed to the degree observed in a
negative control virus that does not express EGFP. In the second system, recombinant
VACVs constitutively expressing six mutant versions of the tet repressor gene (tetR)
shown to bind tet operators in the presence, but not absence of inducers (reverse tetR
genes), were developed. In the presence of tetracyclines (TCs), the recombinant VACVs
exhibited various degrees of repression of EGFP expression, with increasing
concentrations of TCs leading to EGFP repression in a dose dependent manner, and in
some instances, down to the degree observed in a negative control virus. In light of the
renewed interest for the use of VACV as vaccine and therapeutic cancer vectors, the
repressible VACV expression system developed here can be used to tightly regulate
genes essential for VACV replication, thus functioning as a built-in safety mechanism to
conditionally control viral replication.
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CHAPTER 1

INTRODUCTION
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1.1. VACCINATION AND VACCINIA VIRUS
In 1796, Dr. Edward Jenner demonstrated that protection could be achieved
against the highly pathogenic variola virus (smallpox virus) by prior infection with a
related and less pathogenic virus, cowpox virus. Today, this preventative measure is
called vaccination. Between the 19th and 20th centuries, it is theorized that vaccinia
virus (VACV) replaced cowpox as a result of rudimentary smallpox vaccination practices
(Fenner and World Health Organization, 1988). In the 1960s, to finally quell the rampant
spread of smallpox disease that had up to a 30% case fatality rate (Fenner and World
Health Organization, 1988), the World Health Organization (WHO) launched the
smallpox eradication campaign, in which VACV was widely produced and administered
as a live vaccine. In 1979, the WHO succeeded in this feat and smallpox virus was
declared eradicated (Wehrle, 1980, World Health Organization. Global Commission for
the Certification of Smallpox Eradication, 1980). To date, there has been no reemergence of smallpox and its eradication is considered one of the greatest achievements
in the history of medicine.
VACV belongs to the family Poxviridae and has many unique characteristics.
This large complex virus is roughly 200 × 250 nm in size and consists of a dsDNA
genome that is about 190 kb with nearly 200 open reading frames (ORFs) (Moss and Earl,
2001). Viral replication in VACV is distinctive as its genome encodes its own
transcription machinery that allows transcription to occur autonomously within the host
cell cytoplasm, with no evidence of viral gene integration into the host genome (Figure
1.1). Additionally, transcription occurs in an ordered cascade of early, intermediate and
late transcriptional events controlled by specialized VACV promoters. VACV promoters
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have two conserved sequence components, the core and the initiator, that differ between
each temporal promoter. Early mRNAs are detected 20 min post-infection (PI) and levels
peak within the first 100 min. Intermediate mRNAs are detected within 100 min PI and
peaks at about 2 hr PI. Late mRNAs are detected at 140 min PI and increase
continuously for about 48 hr. Posttranscriptional modifications of viral mRNA such as
capping and polyadenylation occurs, but there is no RNA splicing as viral mRNA is
made in the cytoplasm. Subsequently, viral mRNAs are translated by host ribosomes.
The assembly of viral genome and proteins occur in viral factories following complex
morphogenesis and maturation steps that ultimately lead to the generation of new virions.
Mature virions can stay cell associated, bud, or lyse out of the infected host cells (Moss
and Earl, 2001).

1.2. VACCINIA VIRUS AS A VECTOR
With the eradication of smallpox, VACV became one of the best characterized
viruses and has gained much attention in the fields of vaccines and cancer therapies. In
addition to having a wide mammalian host range, VACV is easy to genetically
manipulate (Mackett et al., 1982), is able to carry at least 25 kb of heterologous DNA
while still maintaining its infectivity (Smith and Moss, 1983), and it is able to elicit
potent humoral and cell-mediated immune responses against heterologous antigens
(Tartaglia and Paoletti, 1988). Successful VACV-vectored vaccines have been generated
(Verardi et al., 2012). For example, a recombinant VACV vaccine expressing the
glycoprotein of rabies virus has been used extensively in Europe and North America to
eradicate sylvatic rabies (Pastoret and Brochier, 1996). Also, a recombinant VACV-
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vectored vaccine expressing the fusion and hemagglutinin glycoproteins of rinderpest
virus elicited long-term protective immunity against rinderpest in cattle (Verardi et al.,
2002, Yilma et al., 2003). VACV vectored human vaccines for human
immunodeficiency virus (HIV) (Harari et al., 2008, McCormack et al., 2008, Bart et al.,
2008, Garcia et al., 2011, Goepfert et al., 2011), malaria (Sheehy et al., 2011, Sheehy et
al., 2012), and anthrax (Merkel et al., 2010) are currently undergoing pre-clinical
evaluation or have reached the stage of human clinical trial testing.
Another unique characteristic of VACV is its tropism for cancer cells. VACV has
a predilection to replicate in cancerous cells that can be exploited as delivery systems
(e.g., carrying co-stimulatory molecules to induce immune responses to cancer cells) or
as oncolytic vectors that can lead to the destruction of cancer cells. Currently, cancer
immunotherapies against prostate cancer or oncolytic therapies against solid tumors are
being closely evaluated in clinical trials for efficacy (Verardi et al., 2012). Furthermore,
a dual-functioning oncolytic recombinant VACV expressing the co-stimulatory molecule
granulocyte-macrophage colony-stimulating factor (GM-CSF) is being studied in human
clinical trials as an “armed” oncolytic therapy against cutaneous melanoma (Mastrangelo
et al., 1999, Kirn and Thorne, 2009, Breitbach et al., 2011, Guse et al., 2011).

1.3. SMALLPOX VACCINE
Despite the eradication of smallpox, there are currently significant concerns that
may require widespread smallpox vaccination to resume. For example, one major
concern is the threat of smallpox as a bio-weaponized pathogen (Breman and Henderson,
1998). Unaccounted sources of variola virus may still exist around the globe and
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contribute to this threat. Additionally, advancements in genetic engineering may allow
the laboratory generation of the virus based on published variola virus genomic
sequences (Massung et al., 1994). Also, there could be a release of similar or genetically
engineered poxviruses that are more pathogenic and virulent (Gottschalk and Preiser,
2005). Another concern is the natural re-emergence of a smallpox-like disease caused by
a related virus, such as monkeypox virus (Reynolds et al., 2012). Monkeypox virus is
currently endemic in Africa, but a US outbreak in 2003 due to the importation of African
rodents highlights its potential to re-emerge as a serious public health hazard outside
Africa (Centers for Disease Control and Prevention (CDC), 2003, Reed et al., 2004).
Thus, to prepare for these potential risks, the US has a stockpile of a smallpox vaccine
(Greenberg and Kennedy, 2008, Monath et al., 2004, Nalca and Zumbrun, 2010).

1.4. ADVERSE EVENTS AND CONTRAINDICATIONS
The smallpox vaccine used in the US during the smallpox eradication campaign
(Dryvax, one of the first-generation smallpox vaccines) was prepared from scarified
lesions on calves and it was very efficacious. However, a large subset of the population
is currently deemed contraindicated against live, replication-competent VACV vaccines.
Individuals that are immunosuppressed (HIV/AIDS, transplant, and cancer patients), have
(or had) atopic dermatitis and other skin conditions, that are pregnant, or have cardiac
problems, are especially susceptible to a range of mild to severe adverse events (Casey et
al., 2005, Lane and Goldstein, 2003, Thomas et al., 2008). Mild adverse events include
headache, fever, and pain at the inoculation site. However, severe adverse events include
eczema vaccinatum (in which VACV replicates in areas affected or once affected by
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atopic dermatitis, possibly leading to death), progressive vaccinia (a severe adverse event
that usually affects those that are immunosuppressed as the virus grows uncontrollably in
flesh, skin and even bones, and could also lead to a grave outcome), and encephalitis
(where VACV enters the nervous system, which typically leads to death). In addition,
vaccinated individuals can inadvertently inoculate themselves (autoinoculation) or
inoculate others via contact transmission. A conservative estimate of individuals in the
US that fall within this population is about 25% (Kemper et al., 2002). Affected
individuals, depending on the severity of complications, can be treated with vaccinia
immune globulin (VIG) or antiviral agents such as cidofovir, ST-246, and some tyrosine
kinase inhibitors, but the efficacy of these treatments is questionable (Lane and Goldstein,
2003, Centers for Disease Control and Prevention (CDC), 2009).
There have been great strides taken to increase the safety of smallpox vaccines for
individuals with contraindications (Verardi et al., 2012). For instance, a secondgeneration smallpox vaccine (ACAM2000, a single-clone derivative from the Dryvax
vaccine) was produced in cell culture. While ACAM2000 has improved sterility and is
the current US stockpiled smallpox vaccine, its safety in terms of adverse events was not
improved. In another attempt to increase the safety profile of smallpox vaccines, the
VACV strain Ankara was passaged over 570 times in chick embryo fibroblasts. The
resulting virus, named Modified Vaccinia Ankara (MVA), is highly attenuated in
mammalian hosts. MVA-BN is a prospective third-generation smallpox vaccine
developed by the vaccine company Bavarian Nordic that is currently on fast-track human
clinical trials. However, the protection afforded by MVA as a smallpox vaccine is
uncertain since vaccinated individuals were never exposed to smallpox. Genetic
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engineering has also been used as a tool for the generation of attenuated VACV strains
such as NYVAC, derived from the Copenhagen strain in which 18 nonessential genes
were deleted. NYVAC is also highly attenuated with a restricted host range. Although
these attenuated strains provide a better safety profile, they have numerous limitations.
In particular, highly attenuated strains may require multiple inoculations to elicit a robust
immune response, which is not ideal in the event of the emergence of an orthopoxvirus or
a bioterrorist event (Lane, 2011). Furthermore, they incur higher costs to propagate and
manufacture and as oncolytic therapies, highly-attenuated VACV strains would not be
appropriate, as there is no oncolytic potential in replication-incompetent viruses (Kirn
and Thorne, 2009).

1.5. SIGNIFICANCE
VACV, as a replication-competent virus, has several excellent characteristics that
make it a powerful smallpox vaccine, as well as a vaccine and therapeutic cancer vector.
However, adverse events associated with uncontrollable VACV replication must be
addressed. Thus, an approach to address this limitation is to develop a repressible system
to control gene expression in VACV. The focus of this project is to develop and test
repressible expression systems in VACV by using elements from the tetracycline (tet)
and lactose (lac) operon systems of E. coli to control the expression of a reporter gene,
enhanced green fluorescent protein (EGFP). A future step would be to place a gene that
is essential to VACV viral replication under the control of this repressible system, so that
should an adverse event occur after vaccination or treatment, the expression of the
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essential gene could be repressed, thereby stopping viral replication and most importantly,
the adverse event.

1.6. HYPOTHESIS
The following specific aims will test two different strategies to develop a
repressible VACV expression system, so that in the presence of an operon inducer, the
gene of interest will be repressed (not expressed):

Specific Aim 1: To develop a repressible VACV expression system assembled via a
gene circuit with natural repressors from the lac and tet operons.

We will develop a recombinant VACV (vIRG, vaccinia virus lacI/tetR
Repressible Green fluorescent gene) expressing the natural tetracycline repressor gene
(tetR) under the control of a constitutive early/late VACV promoter (PE/L), and the lacI
gene under the control of an engineered PE/L VACV promoter containing a tet operator
(tetO) sequence (Figure 1.2). EGFP will be under the control of an engineered late
VACV promoter (P11) containing a lacO sequence. In the absence of tetracyclines (TCs),
the TetR repressor binds to the tetO2 operator sequence and prevents the transcription of
lacI, allowing the expression of EGFP. In the presence of TCs, TetR undergoes a
conformational change and does not bind to the tetO2 sequence, allowing LacI to be
expressed and to bind to the lacO sequence, preventing the expression of EGFP.

8

Specific Aim 2: To develop a repressible VACV expression system assembled with
reverse tet repressor mutants and other elements from the tet operon.

We will develop recombinant VACVs (vRG, vaccinia virus Repressible Green
fluorescent gene) expressing reverse mutants of tetR (revtetR) under the control of the
constitutive PE/L promoter, and EGFP under the control of an engineered P11 promoter
containing a tetO2 sequence. In the absence of TCs, revTetR does not bind to the tetO2
operator sequence and allows transcription of EGFP (Figure 1.3). In the presence of TCs,
revTetR undergoes a conformational change and binds to the tetO2 sequence, preventing
the expression of EGFP.

1.7. THE LACTOSE OPERON
The lactose (lac) operon is composed of a set of genes that enable prokaryotes to
use lactose as a carbon source. The regulatory components of the lac operon include a
lactose repressor gene (lacI), DNA operator sequences (lacO), and an inducer, such as the
natural inducer (allolactose) or the synthetic analog isopropyl-1-thio-β-D-galactoside
(IPTG) (Figure 1.4). The lacI gene encodes a homotetrameric LacI repressor protein.
Each monomer contains a DNA binding domain, a hinge region, and an inducer binding
region. There are three different lacO sequences (O1, O2, and O3), with O1 having the
highest affinity for LacI. In 1961, Jacob and Monod elucidated the mechanism of the lac
regulatory system in E. coli (Jacob and Monod, 1961). In this system, E. coli will use
glucose as its primary carbon source. In this case, LacI is expressed constitutively at low
levels and negatively controls genes within the lac operon by binding to operator
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sequences within their independent promoters, thereby leading to the repression of genes
that encode β-galactosidase (LacZ), permease (LacY), and acetyl-transferase (LacA).
However, in the absence of glucose and in the presence of lactose, inherent signals will
initiate the induction of the lac operon. First, lactose becomes converted to its isomer,
allolactose, which then binds LacI, inducing a conformational change so that LacI no
longer binds to the operator sequences (Lewis, 2005, Wilson et al., 2007). RNA
polymerase is then able to bind to the promoter regions that overlap the operators and
allow the transcription of the genes involved in lactose metabolism (Lewis, 2005, Wilson
et al., 2007).

1.8. ALLOLACTOSE ANALOGS
In the history of genetics, the lac operon system was one of the first and best
studied genetic systems. The main way to study the induction of the lac operon was to
measure the induced expression of the enzyme β-galactosidase. Before the 1950s, the
only known methods of measuring β-galactosidase activity were laborious and there was
a need for a more efficient assay. Thus, one of the pioneers in the field of genetics,
Joshua Lederberg, collaborated with chemists to synthesize a substrate for βgalactosidase. One colorless and inexpensive substrate, O-nitrophenyl-β-D-galactosidase
(ONPG), was catalyzed by β-galactosidase into a yellow product that could be
quantitated using a colorimeter. However, ONPG was not an inducer of the system
(Müller-Hill, 1996). In a quest to find an inducer that activated the lac operon without
being metabolized by β-galactosidase, Jacob and Monod also collaborated with chemists
to synthesize new inducers. Of all analogs synthesized, methyl-1-thio-β-D-galactoside

10

(TMG) and isopropyl-1-thio-β-D-galactoside (IPTG) were tested and found to be strong
inducers without being metabolized. IPTG was the strongest inducer and when high
concentrations of IPTG (5 mM) were used, β-galactosidase was induced in prokaryotes
within 3 min (Müller-Hill, 1996). Today, IPTG is commonly used in lac inducible
expression systems in vitro and in vivo to initiate transcription of genes of interest.

1.9. USING THE LACTOSE OPERON TO CONTROL GENE EXPRESSION
The lac system can also be used as a tool to express genes of interest and it has
been adapted for use both in vitro and in vivo. In 1987, Hu and Davidson successfully
developed an inducible system in mammalian cells (mouse L cells), using a plasmid
containing a reporter gene, chloramphenicol acetyltransferase (CAT), under the control of
an engineered early promoter from the Simian Virus 40 (SV40) containing a synthetic
lacO analog sequence and using IPTG (synthetic allolactose analog) to induce CAT
expression (Hu and Davidson, 1987). Similarly, Brown et al. studied a lac inducible
system in HeLa cells, in which IPTG was sufficient to induce the expression of CAT
(Brown et al., 1987). Cronin et al. adapted the lac system to transgenic mice, allowing
the inducible expression of a reporter gene in mice receiving 2 mg/ml of IPTG in
drinking water (Cronin et al., 2001). More relevant to this project, Fuerst et al. adapted
the lac operon to VACV by generating inducible recombinant VACVs that contained a
reporter gene (β-galactosidase) under the control of a late VACV promoter (P11) with a
synthetic lacO placed immediately downstream (Fuerst et al., 1989). The maximal
expression of β-galactosidase in cell culture was induced with 5 mM IPTG (Fuerst et al.,
1989).
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1.10. THE TETRACYCLINE OPERON
Transposon Tn10 of bacteria confers resistance to TCs. The regulatory
components of the tet operon include a tetracycline repressor gene (tetR), operator
sequences (tetO), and an inducer (TCs) (Figure 1.5). The tetR gene encodes a
homodimeric TetR repressor protein, where each monomer contains a DNA binding
domain, a hinge region, and an inducer binding region. There are two different DNA
operator sequences, tetO1 and tetO2, with tetO2 having the highest affinity for TetR. In
the absence of TCs, TetR autoregulates its expression and negatively controls the genes
within the tet operon by binding to the tetO sequences that overlap the tet operon
promoters, thereby leading to the repression of genes that encode TetR and the anti-porter
transmembrane protein complex (TetA) (Hillen and Berens, 1994). In the presence of
TCs, TetR undergoes a conformational change and no longer binds to the operator
sequences (Hillen and Berens, 1994). RNA polymerase is then able to bind to the
promoter regions, allowing the expression of TetA, which aids in the efflux of TCs.

1.11. TETRACYCLINE DRUG CLASS DERIVATIVES
TCs are produced by microbes and are known to inhibit translation of other
prokaryotes to establish a territorial advantage (Greenwald et al., 2001). The primary
mechanism of action of TCs is to selectively block the acceptor site (A-site) of
prokaryotic ribosomes, thus preventing the linkage of a new amino acid to the nascent
polypeptide chain and ultimately leading to demise of the cell. The tet operon is an
adaptive genetic mechanism that leads to TC removal so that prokaryotes can resist its
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negative effects. TC derivatives have been synthesized in which drugs within this class
share the same backbone and differ mostly in functional groups (Greenwald et al., 2001).
Of the drugs within this class, the synthetic TCs minocycline and doxycycline (DOX) are
widely used in medicine, animal health, and agriculture. However, due to multi-drug
resistance, newer derivatives such as glycylcyclines are being investigated in vitro and in
vivo. Another tetracycline widely used in prokaryotic expression systems is
anhydrotetracyline (ATC), which has increased affinity for TetR and minimal
antibacterial activity.

1.12. USING THE TETRACYCLINE OPERON TO CONTROL GENE
EXPRESSION
Like the lac operon, the tet operon has been used to generate inducible systems to
control the expression of a gene of interest. In 1988, Gatz and Quail first adapted the tet
operon to tobacco plant cells by cotransfecting a plasmid expressing the reporter gene
CAT under the control of the cauliflower mosaic virus (CaMV) 35S promoter with two
tetO2 sites, and another plasmid expressing tetR under the constitutive control of CaMV
35S.
In a design of a new mammalian inducible system, Gossen et al. randomly
mutagenized the tetR gene and screened for mutants that yielded the reverse phenotype in
the presence of DOX. One reverse tetR mutant characterized contained the amino acid
mutations E71K, D95N, L101S, and G102D (Gossen et al., 1995). Then, a reverse
tetracycline transactivator (rtTA) was generated by fusing the reverse tetracycline
repressor gene (revtetR) with a transcriptional activator (TA) from the VP16 gene of
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herpes simplex virus. In the presence of TCs, rtTA binds to the tet responsive element
(TRE), a modified early CMV promoter that lacks strong enhancer elements (PminCMV)
and contains seven repeats of tetO2, promoting transcription of a gene of interest. This
TC-inducible system, referred to as the Tet-On system, became a useful tool for inducible
control of gene expression in eukaryotic cells and transgenic mice.
In 2000, Urlinger et al. wanted to improve the original rtTA system as it was not
very sensitive to DOX and had a high basal level of transcriptional activity in the absence
of DOX (Urlinger et al., 2000). The rtTA gene was subjected to direct and random
mutagenesis and six novel mutants (with two to five amino acid changes) that exhibited
the reverse TetR phenotype were obtained. Mutant rtTA-S3 (T26A and D95G) resulted
in somewhat lower background levels of expression, but in the presence of inducer a
reporter gene (luciferase) was expressed at lower levels than the original rtTA. Mutant
rtTA-S2 (E19G, A56P, D148E, and H179R) had a similar activation potential as rtTA,
but a significantly lower background activity. The mutational contributions in rtTA-S2
were explored by generating mutants rtTA-19/56 (E19G and A56P) and rtTA-148/179
(D148E and H179R). rtTA-19/56 had a stringent reverse phenotype and minute
background activity, while mutant rtTA-148/179 was found to have lost the reverse
phenotype. To increase the sensitivity of the system to low concentrations of DOX,
rtTA-19/56R mutants were grown in media containing 10 ng/ml DOX (less than the
initial dose used of 10 µg/ml) and subjected to additional mutagenesis. Mutant rtTA-M1
(S12G, E19G, and A56P) was recovered with increased sensitivity to DOX and a
stringent reverse phenotype. The mutant rtTA-M2 was generated to have enhanced
activation and high sensitivity to DOX, which had a combination of mutations from
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rtTA-148/179R and rtTA-M1. rtTA-M2 had stringent reverse phenotype, low
background expression properties, and a higher sensitivity towards DOX, and is currently
a useful tool for inducible control of gene expression, especially in transgenic mice.
However, a tet system utilizing the VP16 transactivator with a minimal CMV promoter
would not function in VACV, as VACV transcription is driven by inherent VACV
promoters.
Other revTetR mutants were also explored by Scholz et al. with the goal to find
the minimum number of amino acids required to reverse the phenotype of TetR in E. coli
(Scholz et al., 2004). The tetR gene was randomly mutagenized and selected using a TCinducible β-galactosidase expression system where in the absence of inducer, revTetR
cannot bind to its operator and therefore allows expression of the reporter gene, while in
the presence of inducer, revTetR represses the expression of β-galactosidase. This
system was adapted to be dependent on ATC, a TC that does not confer antibiotic activity.
A total of 41,000 mutants were screened, of which 112 mutants exhibited the revTetR
phenotype. Ultimately, two different revTetR mutants having a single amino acid
mutation (L17G or V99E) were found. Both revTetR mutants resulted in the expression
of approximately 90% β-galactosidase activity in the absence of the inducer (ATC) and
only about 3% β-galactosidase activity in the presence of the inducer.
In 2000, Traktman et al. developed TC-inducible VACVs by inserting a tetO
operator sequence between the transcriptional and translational start sites of VACV genes,
enabling their expression to be tightly regulated by TCs (Traktman et al., 2000).
Traktman and others have used the TC-inducible system as a tool for regulation of
specific VACV genes, thereby leading to a better understanding of basic biological
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properties of VACV. Weber, Verardi et al. (unpublished data) used a VACV TCinducible system developed in the Verardi Lab for a more practical application as a builtin safety mechanism for VACV based on the inducible expression of interferon-γ (IFN-γ).
The IFN-γ gene acts as a safety gene in vivo when expressed by VAVC, attenuating the
virus by more than a million-fold. Immunodeficient mice inoculated with high doses of
VACV constitutively expressing IFN-γ are able to rapidly and completely clear infection
(Legrand et al., 2005). In this new application of the inducible system, TetR (the
repressor) is constitutively expressed and binds to an operator (tetO2) placed downstream
of a VACV promoter (Weber et al., 2007), blocking transcription and expression of the
IFN-γ gene. Thus, in the absence of TCs, VACV replicates normally, eliciting full
immune responses and retaining its oncolytic potential. When complications arise or are
suspected, TC treatment causes TetR to undergo a conformational change so that it no
longer binds to the operator. This unblocks the promoter and allows expression of IFN-γ,
resulting in complete clearance of the virus. Since this inducible built-in safety
mechanism is based on the expression of a cytokine (IFN-γ), which has the potential to
cause untoward effects, an alternative built-in safety mechanism is greatly needed.
Consequently, the development of repressible systems in VACV could provide a built-in
safety mechanism that addresses these concerns by allowing us to repress the expression
of VACV genes essential for viral replication.
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1.13. FIGURES

FIGURE 1.1.. Simplified VACV rreplication cycle. Once VACV enters the host
ho cell, an
ordered cascade of early, intermediate, and late transcriptional events occur that lead to
the morphogenesis and maturation of progeny viral particles (virions).
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2. Tetracycline
Tetracycline-controlled
controlled repression of EGFP expression in the vIRG
FIGURE 1.2.
system (lacI/tetR gene circuit). The tetR gene is transcribed constitutively (under PE/L)
and in the absence of TCs
TCs, TetR binds to tetO2, blocking expression of lacI by the
upstream PE/L promoter and allowing EGFP expression. In the presence of TCs, TetR
undergoes a conformational change that does not allow it to bind onto the operator and
block lacI expression. The LacI repressor is then made and it blocks the transcription of
EGFP by binding onto the lacO sequence downstream from the P11 promoter.
promoter
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3. Tetracycline
Tetracycline-controlled
controlled repression of EGFP expression in the vRG
FIGURE 1.3.
system (revTetR). In the absence of TCs, revTetR does not bind to tetO2, allowing
expression of EGFP.. In the presence of TCs, revTetR
evTetR undergoes a conformational
change that allows it to bind onto the tetO2 operator, blocking the transcription of EGFP
from the upstream P11 promoter
promoter.
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4. Genetic m
mechanism of the lac operon. In the absence of inducer, LacI
FIGURE 1.4.
repressor proteins bind onto the operator regions to negatively control the expression of
lacZ, lacY, and lacA.. In the presence of inducer, LacI undergoes a conformational
change so that it can no longer bind to the lacO operators, thus allowing the expression of
the genes required for the metabolism of lactose.
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FIGURE 1.5.
5. Genetic m
mechanism of the tet operon. In the absence of inducer (TCs),
the TetR repressor binds onto operator regions (tetO1 and tetO2) to negatively control the
expression of tetA and tetR
tetR. In the presence of inducer (TCs),, TetR undergoes a
conformational change so that it can no longer bind to the operators, thus allowing the
expression of TetA required for the efflux of tetracycline.
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CHAPTER 2

DEVELOPMENT OF A REPRESSIBLE VACCINIA VIRUS
EXPRESSION SYSTEM ASSEMBLED VIA A GENE CIRCUIT
WITH NATURAL REPRESSORS FROM THE LAC AND TET
OPERONS
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2.1. ABSTRACT
A recombinant vaccinia virus (VACV) that contains elements from the lactose
(lac) and the tetracycline (tet) operon systems of E. coli arranged in a gene circuit to
conditionally control the expression of a reporter gene, enhanced green fluorescent
protein (EGFP), was developed. In the absence of inducers, EGFP expression in infected
cells was detectable, but less than a positive control virus expressing the gene
constitutively under the same promoter. However, in the presence of increasing
concentrations of a lac operon inducer alone (isopropyl-β-D-thiogalactoside, IPTG),
EGFP expression increased in a dose dependent manner and at high IPTG concentrations,
expression reached the same levels as a positive control virus. Additionally, in the
presence of increasing concentrations of the tet operon inducer only (doxycycline, DOX),
EGFP expression decreased in a dose dependent manner and at high concentrations of
DOX, expression was repressed to the degree observed in a negative control virus that
does not express EGFP. Thus, a dimmer-like modulation of expression can be achieved
using different concentrations of either inducer. Furthermore, EGFP expression was
modulated in the presence of both inducers, much like a double rheostat circuit, and even
after infection. This modulatory expression system has potential applications for
studying VACV genes in their life cycle or a means to regulate the expression of genes
for the development of novel vaccines and cancer therapies.
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2.2. INTRODUCTION
Vaccinia virus (VACV) belongs to the family Poxviridae, has a 190 kb dsDNA
genome, and autonomously replicates in the host cell cytoplasm. Historically, VACV
has gained much attention. First, it was used as a vaccine to eradicate variola virus,
which caused smallpox disease (Fenner and World Health Organization, 1988). After
this great achievement, advancements in genetic engineering allowed VACV to be used
as a viral vector and to be studied in more detail (Mackett et al., 1982, Mackett et al.,
1984, Moss, 1991, Moss, 1996). A popular technique used to study this complex virus is
to place VACV genes under the conditional control of elements from either the
tetracycline (tet) or the lactose (lac) operon from E. coli (Fuerst et al., 1989, Traktman et
al., 2000), so that the role of the gene in the viral life cycle can be studied in the absence
or presence of the respective operon inducers. In addition, these inducible expression
systems can have practical applications to regulate the expression of VACV or
heterologous genes, as there is a renewed interest for using VACV as a live viral vector
for smallpox vaccines, heterologous vaccines, and cancer therapies (Verardi et al., 2012).
The construction of these inducer-dependent VACV recombinants entails an E.
coli repressor gene (lacI or tetR) that is constitutively expressed by a VACV early/late
promoter and an E. coli operator sequence (lacO or tetO) that is placed downstream from
a VACV promoter and upstream from the start site of a VACV gene. In the absence of
lac operon inducers, such as isopropyl-β-D-thiogalactoside (IPTG), or tet operon inducers,
tetracyclines (TCs) such as tetracycline (TET) or doxycycline (DOX), the transcription of
the gene of interest is blocked and the observed phenotypes (e.g., smaller plaque
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phenotype or no mature virion formation via electron microscopy) can be interpreted to
yield information on the essentiality and functionality of a gene of interest.
Although inducible systems are useful in characterizing VACV genes, only the
induction of gene expression and the resulting phenotype can be effectively studied.
After induction and infection, the removal of the inducer (e.g., by washing the cells with
medium) is difficult, especially if expression at certain time points is being characterized.
The inducer already present within the cell will not lead to full repression of gene
expression in a timely fashion. Thus, a new modulatory system that allows for either
quick repression or induction of gene expression by the addition (and not removal) of
particular inducers offers a new and efficient way of studying the role of genes in the
viral life cycle.
Despite the renewed interest in VACV as a replication competent vaccine and
therapeutic vector, there is a growing subset of the population that is contraindicated
against VACV vaccination as the infection could lead to severe adverse events, including
death. This population includes the immunosuppressed, cancer therapy patients,
individuals with atopic dermatitis, and individuals with heart conditions (Kemper et al.,
2002). Thus, an approach to increase the safety of VACV vectors is to place a gene
essential to viral replication under the control of a repressible system, which could serve
as a built-in safety system. In cases where adverse events were to occur, transcription of
a gene essential to viral replication could be blocked upon administration of an inducer,
thus stopping the replication of the virus and most importantly, the progression of the
adverse event.
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In this study, elements from both the lac and the tet operons of E. coli, arranged
via a gene circuit, were used to generate a recombinant VACV called vIRG, that is
dependent on TCs to repress the expression of a reporter gene, enhanced green
fluorescent protein (EGFP). Additionally, we found that in the presence of IPTG, EGFP
expression can be induced. Thus, we describe a system that can modulate the EGFP
expression much like a dimmer or double rheostats that can be controlled independently
in the presence of appropriate inducers.

2.3. MATERIALS AND METHODS

Viruses and Cell Cultures. African green monkey kidney (BS-C-1) and human (HeLa
S3) cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% TET tested fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA)
at 37°C in 5% CO2. A clone derived from the Western Reserve (WR) strain of VACV
(ATCC VR-2035) and all recombinant VACVs were propagated in BS-C-1 and HeLa S3
cells and titered by plaque assay in BS-C-1 cells.

Transfer Vectors. The construction of the vIRG transfer vector (pAT015) is detailed in
Figure 2.1. Plasmid pAT009 is a designed synthetic plasmid (DNA2.0, Menlo Park, CA)
that contains the lacI ORF, a multiple cloning site (MCS), and the late VACV P11
promoter with a synthetic 22 bp lacO sequence (Sadler et al., 1983) located immediately
downstream from the promoter transcriptional start site. The restriction sites BglII and
BspEI flank the entire construct within pAT009 and this BglII-BspEI fragment was
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cloned into the same sites of pSMART15 (Weber et al., 2007), generating pAT014.
pSMART15 contains tetR under the control of a strong synthetic VACV early/late
promoter (PE/L) (Chakrabarti et al., 1997), the DsRed-Express gene under the control of
an additional (back-to-back) VACV PE/L promoter with a 19 bp tetO2 sequence placed
directly downstream from the late transcriptional start site, and the gpt-gus fusion gene
under the control of a synthetic early/late VACV Psel promoter (Hammond et al., 1997),
flanked by segments of the VACV thymidine kinase (TK) gene (left, TKL and right, TKR),
which allow for homologous recombination with the VACV TK genomic region. The
final transfer vector (pAT015) was generated by transferring the EGFP gene (Thastrup et
al., 2001) from pAT010 (DNA2.0) into the BamHI and EagI sites of pAT014. Similarly,
a transfer vector with EGFP under the control of P11 lacking the tetO2 sequence was also
generated to serve as a positive control. Additionally, transfer vectors with lacI under
the control of PE/L with multiple operator sequences and arrangements were generated,
with two tandem tetO2 sequences separated by 2 bp (2×tetO2(2)) or 11 bp (2×tetO2(11)),
as well as tandem tetO1 and tetO2 operators separated by 11 bp (tetO1/O2(11)) (Yao et al.,
1998). These transfer vectors were generated by replacing the BglII-XmaI fragment of
pAT015 (containing the PE/L-tetO2 fragment) with the respective promoter fragments
from plasmids pSMART16, pSMART17, and pSMART18 (Weber et al., 2007).

Generation of Recombinant VACVs. Recombinant VACVs vIRG (1×tetO2), vIRG2
(2×tetO2(2)), vIRG3 (2×tetO2(11)), vIRG4 (tetO1/O2(11)), and vRGc (no tetO, positive
control virus constitutively expressing EGFP) were generated via standard homologous
recombination by transfection of the transfer vectors into BS-C-1 cell monolayers
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infected with VACV strain WR (also used as the negative control) at a multiplicity of
infection (MOI) of 0.05 plaque-forming units (PFU)/cell. Recombinant VACVs were
plaque purified in selection medium (25 µg/ml mycophenolic acid, 250 µg/ml xanthine,
15 µg/ml hypoxanthine, in the absence or presence of 5 mM IPTG); plaques were
visualized either with substrate 5-bromo-4-chloro-3-indolyl-β-D-glucuronide (X-Gluc) or
by selecting and collecting only EGFP+ expressing plaques detected via fluorescence
microscopy. The purity of the recombinant VACVs (absence of parental virus) were
confirmed by checking multiple dilutions of stocks in selection-free media (with 5 mM
IPTG) for the presence of non-fluorescent (EGFP-) plaques. High titer stocks of each
recombinant VACV were generated by infecting HeLa S3 cells at an MOI of 0.1.
Infected cells were harvested 3 days post-infection (DPI) by centrifugation at 200 × g for
10 min. Cells were then lysed by freezing and thawing, sonicated, and trypsinized.
Finally, cell lysates were clarified to remove contaminating cell debris by a second round
of sonication and centrifugation at 200 × g for 5 min.

Determination of EGFP Expression. BS-C-1 cell monolayers in multiwell culture
plates were infected with vIRG, vRGc, or WR (30 PFU or an MOI of 1) in the presence
of medium only or various concentrations of IPTG, DOX, TET, or anhydrotetracycline
(ATC). At 2 DPI, EGFP expression by isolated plaques or infected cells were determined
by quantitative fluorescence microscopy (as described below). In certain instances, cell
monolayer, were washed with 1× phosphate-buffered saline (PBS) pH 7.2, resuspended
in equal parts of 1× PBS and 2% neutral buffered formalin (1% final concentration), and
analyzed with a fluorescence plate reader (as described below) within 24 hr.
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Modulation of EGFP Expression. BS-C-1 cell monolayers in multiwell culture plates
were infected with vIRG, vRGc, or WR (30 PFU or an MOI of 1) in the presence of
medium only or various concentrations of DOX and IPTG, and 2 DPI plaques were
imaged via fluorescence microscopy. Additionally, HeLa S3 cell monolayers were
infected at an MOI of 1 in various concentrations of DOX or IPTG, and 24 hr later cells
were trypsinized for 5 min on plate shaker (low setting), centrifuged 300 × g for 10 min,
resuspended in equal parts of 1× PBS and 2% neutral buffered formalin (1% final
concentration), and analyzed by flow cytometry within 24 hr. Briefly, 10,000 cells were
analyzed in a FACScan (Becton Dickinson, Rutherford, NJ) flow cytometer and the
CellQuest software (Becton Dickinson) was used to gate cell populations based on
forward and side scatter and to determine the mean fluorescence (488 nm excitation and
530/30 emission).

EGFP Expression Kinetics. First, the inducibility of EGFP expression was tested by
infecting BS-C-1 cell monolayers with vIRG, vRGc, or WR at an MOI of 1 in the
presence of 1 mM IPTG added at the time of infection or several times post-infection.
Cells were imaged and quantified at each time point as described below. In addition, the
repressibility of EGFP expression was tested by first infecting cells as above in the
presence of 1 mM IPTG, and then adding DOX (100 ng/ml) at various time points postinfection.
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Imaging and Image Quantification. Infected cells and plaques were imaged using an
inverted fluorescence microscope (Axio Observer D1, Carl Zeiss, Thornwood, NY) with
or without a green bandpass filter (XF100-2, Omega Optical, Brattleboro, VT). EGFP
expression levels were quantified with the AxioVision software, release 4.8.1 (Carl Zeiss).

Fluorescence Quantification with a Microplate Reader. The fluorescence readings of
infected cells were obtained with a fluorescence plate reader (Synergy HT Multi-Mode
Microplate Reader, BioTek Instruments, Winooski, VT) using a 485/20 nm excitation
and a 528/20 nm emission filter pair. EGFP expression levels are quantified with the
KC4 v3.4 software (BioTek Instruments).

2.4. RESULTS

EGFP Expression Levels by vIRG in the Absence of lac and tet Operon Inducers is
Lower than Expected. In the absence of inducers, BS-C-1 cells infected with vIRG, a
negative control virus (WR), or a positive control virus (vRGc) all displayed the expected
cytopathic effect (CPE) 2 DPI and when observed under brightfield microscopy (Figure
2.2). Under fluorescence microscopy, vIRG infected cells displayed detectable levels of
EGFP expression (Figure 2.2). However, the observed EGFP expression levels were
significantly lower than those observed for the positive control virus (vRGc) (Figure 2.2).
This result was unexpected as we anticipated that vIRG would be completely unrepressed
in the absence of inducers.
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IPTG Induces Higher EGFP Expression Levels by vIRG in a Dose Response
Manner. A likely mechanism for the observed intermediate level of EGFP expression by
vIRG is the leaky expression of lacI under the control of the strong early/late synthetic
promoter PE/L. In such case, any expressed LacI repressor would bind to the tetO2
sequence downstream from the EGFP promoter, reducing EGFP expression. To test this
possibility, BS-C-1 cells were infected with vIRG in the presence of 1 or 5 mM of IPTG,
a lac operon inducer. Previously, concentrations of IPTG between 0.1-5 mM were used
in a lac inducible expression system in VACV (Fuerst et al., 1989). The CPE observed
by brightfield microscopy 2 DPI in cells treated with 5 mM IPTG was indistinguishable
from the CPE observed in cells that did not receive IPTG (Figure 2.3). Moreover,
fluorescence microscopy indicated that infected cells treated with IPTG displayed
significantly higher levels of EGFP expression levels when compared with untreated cells
(Figure 2.3). To quantitate the levels of EGFP expression, cells were infected at an MOI
of 1 in the presence of 1 mM IPTG (Figure 2.4) and analyzed by quantitative
fluorescence microscopy (Figure 2.5). The addition of IPTG resulted in EGFP
expression levels by vIRG that were at the same levels as vRGc. This would be expected
since any potential LacI repressor present (e.g., by leaky expression) should undergo a
conformational change in the presence of IPTG so that it no longer binds onto its cognate
lacO sequence. Furthermore, when increasing concentrations of IPTG were added to
cells infected with vIRG, EGFP expression levels increased in a dose dependent manner
(Figure 2.6). Therefore, in a system in which basal EGFP expression levels were
intermediate, the addition of IPTG resulted in an inducible expression system.
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DOX Completely Represses EGFP Expression by vIRG in a Dose Response Manner.
Although we were able to demonstrate that EGFP expression was inducible, our initial
goal was to develop a system that was able to represses EGFP expression in the presence
of tet operon inducers. Previously, a variety of TET derivatives have been used in tet
systems. For example, TET and DOX at concentrations between 0.1-1 µg/ml were
successfully used in the inducible VACV expression systems (Traktman et al., 2000,
Weber et al., 2007). In addition, ATC (a TET derivative with minimal antibiotic activity)
has been used at concentrations of 0.4 µM (185 ng/ml) in bacterial expression systems
(Scholz et al., 2003, Scholz et al., 2004). Thus, to determine if EGFP expression was
repressible, DOX, TET, and ATC were added to cells infected with vIRG and expression
of EGFP was quantified with a fluorescence microplate reader (Figure 2.7). At 2 DPI, no
detectable differences in CPE were observed between any TC-treated and untreated cells
via brightfield microscopy (data not shown). In the presence of TCs, EGFP expression
was repressed to differing degrees depending on the type and concentration of TC used.
The repression of EGFP expression was very sensitive to DOX, followed by ATC and
TET. DOX at 1 ng/ml was sufficient to repress EGFP expression to the level of the
negative control virus, WR. At higher concentrations of ATC, there was a small
detectable increase in fluorescence, which was also confirmed by fluorescence
microscopy (data not shown). Additionally, ATC is associated with side effects such as
cutaneous phototoxicity and Fanconi-type syndrome in humans (Burgos et al., 2011).
Therefore, DOX was used for further characterization, as it is the most sensitive in
repressing EGFP expression, it does not exhibit a high degree of autofluorescence, and is
an FDA approved drug.
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To demonstrate that EGFP expression levels can be repressed to fluorescence
levels compared to WR, cells were infected with WR or vIRG in the absence or presence
of 100 ng/ml of DOX (Figure 2.8). In the absence of DOX, EGFP expression (measured
in arbitrary fluorescence units) by vIRG was higher than in WR-infected cells. In the
presence of DOX, EGFP expression by vIRG was repressed to the same level as WR.
WR fluorescence levels stayed the same in the absence or presence of DOX. Finally, as
increasing concentrations of DOX were added to cells infected with vIRG, EGFP
expression levels decreased in a dose dependent manner and at 10 ng/ml, EGFP
expression was repressed to levels comparable to WR (Figure 2.9). Thus, we were able
to show that this novel VACV expression system has the ability to display both inducible
and repressible gene expression phenotypes in the presence of the appropriate inducers.

Rheostat Modulation of EGFP Expression. The inducible and repressible capabilities
of vIRG allow the modulation of EGFP expression in a dimmer-like fashion, using the
appropriate inducers. To demonstrate the range of EGFP expression in this system, cells
were infected with vIRG in the absence or presence of increasing concentrations of DOX
or IPTG. As observed initially, cells infected with vIRG in the absence of inducers
(media only) yielded intermediate levels of EGFP expression (Figure 2.10). EGFP
expression could be repressed by treating with increasing concentrations of DOX, or
could be induced by adding increasing concentrations of IPTG.
Flow cytometry (a more sensitive tool to detect EGFP expression) was also used
to quantify the range of gene expression that can be achieved with vIRG. In a
preliminary study, HeLa S3 cells were infected with vIRG, WR or vRGc in the absence
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or presence of varying concentrations DOX or IPTG (Figure 2.11). vIRG exhibited the
same trends of repression and induction as observed by fluorescence microscopy and
microplate reader. However, EGFP expression did not seem to be fully repressed to WR
levels or induced to the same levels of vRGc. These results could be due to a variety of
factors such the use of a different cell line, small number of cells analyzed, acquisition or
analysis settings (such as the gating of infected cells, since at an MOI of 1 only about
63% of the cells are expected to be infected), and the fact that control virus measurements
were taken in the absence of inducers. Nonetheless, both methods show that EGFP
expression by vIRG could be modulated in the presence of increasing concentrations of
DOX or IPTG.
Next, we tested the system in BS-C-1 cells infected with vIRG in the presence of
varying concentrations of both DOX and IPTG (Figure 2.12). EGFP expression in these
conditions followed the same trends of induction in the presence of increasing
concentrations of IPTG and repression in the presence of increasing concentrations of
DOX. Furthermore, in the presence of the highest concentration of DOX (where EGFP
expression is similar to the level of the negative controls virus), the addition of increasing
concentrations of IPTG to the induction of EGFP expression, without the removal of
DOX. Conversely, in the presence of the highest concentration of IPTG (that induces
EGFP expression to maximal levels), the addition of DOX leads to the repression of
EGFP expression. Thus, the vIRG system also allows a double rheostat-like modulation
of gene expression, so that two independent “switches” (inducers) can be used to
simultaneously modulate EGFP expression.
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Kinetics of EGFP Induction by vIRG. To study the kinetics of EGFP expression by
vIRG, BS-C-1- cells were infected with vIRG, WR, or vRGc and treated with IPTG (1
mM) at various time points post-infection and EGFP expression was quantified at every
time point (Figure 2.13). The different IPTG treatments did not alter the EGFP
expression kinetics for WR and vRGc. As observed initally, in the absence of IPTG,
vIRG expressed intermediate levels of EGFP (fluorescence measurements are higher than
WR). EGFP expression by vIRG treated with IPTG at 0, 3 and 12 hr did not differ
significantly and peaked at 48 hr post-infection (similar to vRGc). This is most likely
due to the late promoter (P11) that drives EGFP expression in this system. Conversely,
EGFP expression by vIRG increased dramatically after the addition of IPTG between 18
and 48 hr post-infection. Thus, induction of this system can be tightly regulated even
after infection.

Kinetics of EGFP Repression by vIRG. To study the kinetics of repression of EGFP
expression, BS-C-1 cells were infected with vIRG in the presence of 1 mM IPTG (to
induce expression) and then treated with DOX (100 ng/ml) at several time points postinfection (to repress expression) (Figure 2.14). As observed initially, vIRG grown in
medium only had measurable levels of EGFP expression (fluorescence higher than WR).
In the presence of IPTG only, vIRG expressed levels of EGFP comparable to the positive
control virus (vRGc). In the presence of IPTG, addition of DOX between 0-12 hr postinfection produced expression curves that were similar to vIRG grown in the absence of
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DOX. Thus, DOX treatment between 0 and12 hr post-infection halts the expression of
EGFP. Again, this is likely due to the late P11 promoter that drives expression of EGFP
to high levels only after 12 hr post-infection, as observed in vRGc. Conversely, cells
infected with vIRG in the presence of IPTG and treated with DOX at 18 and 24 hr
displayed a significant increase in EGFP expression before DOX exposure; however,
EGFP expression was repressed and eventually plateaued after DOX exposure. Thus,
repression in this VACV gene expression system can be tightly regulated even after
infection.

Addition of tetO Operators in Different Numbers and Arrangements Does Not
Prevent Leaky Expression of LacI. A number of recombinant VACVs derived from
vIRG were developed with the lacI gene under the control of the PE/L promoter with
multiple tetO operator sequences and arrangements: two tandem tetO2 sequences
separated by 2 bp (2×tetO2(2), vIRG2) or 11 bp (2×tetO2(11), vIRG3), as well as tandem
tetO1 and tetO2 operators separated by 11 bp (tetO1/O2(11), vIRG4), as described by
Weber et al. (Weber et al., 2007). BS-C-1 cells were infected with the different viruses in
the absence or presence of 5 mM IPTG, and isolated plaques were imaged by
fluorescence microscopy (Figure 2.15). The levels of EGFP expression in the absence of
IPTG do not differ between the different recombinant VACVs, indicating that the
different number and arrangements of tetO operators tested were not able to stop leaky
expression of LacI.
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2.5. DISCUSSION AND CONCLUSIONS
We developed a gene modulation system in VACV that is not only repressible,
but also inducible in the presence of the appropriate inducers. However, it was not our
initial expectation that vIRG would also result in an inducible system as the development
of this project initially focused on the design of a repressible system. The vIRG
expression system is able to exhibit both inducible and repressible capabilities likely due
to the unexpected leaky expression of lacI. Therefore, in an attempt to control lacI leaky
expression, new transfer vectors were designed with the addition of tandem tetO operator
sequences (in different arrangements) placed downstream from the PE/L promoter
controlling lacI expression. However, preliminary studies indicate that this strategy does
not seem to lower the leaky expression of lacI significantly. This is likely because
repression of early VACV promoters using repressor proteins such as LacI and TetR does
not seem to be achievable using this technology, as evidenced by recent unpublished data
from the Verardi Lab (Weber, Verardi et al, unpublished data). Thus, an alternative
method to control this potential leaky expression of lacI is to change the current lacI
promoter (the early/late PE/L promoter) to the late P11 promoter, which has been
successfully used to tightly control gene expression in VACV (C. Hagen, unpublished
data).
Based on this theory, we can outline a potential gene circuit mechanism
underlying the control of gene expression in vIRG. The constitutive expression of tetR
should provide a continuous supply of the TetR repressor protein (Figure 2.16). In the
absence of inducers, there is probably an expression timing issue that leads to
intermediate levels of EGFP expression. We know that early transcription occurs soon
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after infection (virus entry). If tetR and lacI are under the control of the same strong PE/L
promoter, then both lacI and tetR expression will ensue at rates that are initially the same.
Thus, immediately after infection, lacI is being expressed, albeit at low levels. As the
TetR protein accumulates, then it can finally bind to tetO operator sequences to halt
further transcription of lacI. However, since the reporter gene (EGFP) is under a late
promoter, any LacI already present in the cell will interfere with its expression, and hence
the intermediate levels of expression.
In conclusion, we have demonstrated a novel modulatory expression system in
VACV that is sensitive to both the lac and the tet operon inducers, is inducible as well as
repressible, is dose-dependent, and allows temporal regulation of gene expression even
after infection and without the removal of the previous inducer. This novel expression
system has an array of potential applications in basic virology (e.g., the study of VACV
genes and their function or temporal essentiality) and translational animal and human
medicine (e.g., safer vaccines and therapeutic viral vectors). One application would be to
regulate a VACV gene of interest using this system and determine the amount and timing
of expression necessary to allow morphogenesis and replication, so that DOX and IPTG
could be used like independent rheostats controlling gene expression. In another
application, a gene that is known to be essential for viral replication could be placed
under the control of this system to serve as a potential safety mechanism for VACV
vectors used for vaccination or cancer therapy. If VACV-associated complications were
to arise, DOX administration would lead to the repression of the gene, stopping viral
replication and halting the adverse event.
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2.6. FIGURES

FIGURE 2.1. Construction of the transfer vector pAT015 for the generation of
vIRG. The cloning steps leading to the generation of the final transfer vector are shown.
pAT015 contains the gpt--gus fusion gene under the control of an early/late
y/late VACV
promoter (PSel), the EGFP gene under the control of an engineered P11 promoter with a
lacO sequence located directly downstream, the tetR gene under the control of a
constitutive strong early/late promoter ((PE/L), and the lacI gene under the control of an
additional (back-to-back)
back) PE/L promoter with a tetO2 sequence located directly
downstream, all flanked by TKL and TKR sequences that direct recombination with the
TK gene of VACV.
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inducers
FIGURE 2.2. EGFP expression llevels in the absence of lac and tet operon inducers.
BS-C-1 cells infected with WR, vIRG, or vRGc in the absence of inducers displayed
typical CPE 2 DPI, and single isolated plaques were imaged by brightfield and
fluorescence microscopy. vIRG
vIRG-infected cells displayed significantly lower fluorescence
levels when compared to vvRGc (positive control virus),, but significantly higher
fluorescence levels when compared to WR (negative control virus).
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FIGURE 2.3. Cells
ells infected with vIRG in the presence of 1 mM IPTG express
higher levels of EGFP. BS-C-1 cells were infected with vIRG in the absence (- IPTG)
or presence (+ IPTG) of 5 mM IPTG and imaged 2 DPI. All infected cells displayed
similar CPE and single isolated plaques were imaged by brightfield and florescence
microscopy. Cells infected with vIRG in the presence of IPTG displayed high levels of
fluorescence when compared to infected cells not treated with IPTG.
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FIGURE 2.4. EGFP expression levels in vIRG
vIRG-infected
infected cells treated with IPTG
IPT are
high. BS-C-1 cells were infected at an MOI of 1 with WR, vRGc, or vIRG in the
absence (- IPTG) or presence (+ IPTG) of 1 mM IPTG, and 2 DPI cells were imaged by
fluorescence microscopy. The EGFP expression levels detected in vIRG-infected
vIRG
cells
treated
ated with IPTG were higher than in the absence of IPTG.
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BS-C-1
1 cells infected with
FIGURE 2.5. Quantification of EGFP expression in BS
vIRG in the absence or presence of IPTG. BS-C-1 cells were infected at an MOI of 1
with WR, vRGc, or vIRG in the absence (- IPTG) or presence (+ IPTG) of 1 mM IPTG,
and 2 DPI cells were imaged by ffluorescence microscopy and EGFP expression was
quantified. The EGFP expression levels detected in vRGc and vIRG-infected
infected cells
treated with IPTG were indistinguishable and higher than vIRG-infected
infected cells in the
absence of IPTG. Error bars are SEM, n=3.
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FIGURE 2.6. IPTG induces EGFP expression by vIRG in a dose response manner.
BS-C-1 cells were infected at an MOI of 1 with WR, vIRG, or vRGc in the absence
ab
or
presence of increasing concentrations of IPTG
IPTG, and 2 DPI cells were imaged by
fluorescence microscopy and EGFP expression was quantified
quantified. EGFP expression by
vIRG followed a dose-response
response curve. Error bars are SEM, n=3.

49

TCs. BS-C
C-1 cells were
FIGURE 2.7. EGFP expression by vIRG is repressible by TCs
infected
nfected at an MOI of 1 with vIRG or WR in the absence or presence of varying
concentrations of TET, DOX
DOX, or ATC, and 2 DPI EGFP expression was quantified with a
microplate reader. EGFP expression levels were repressed in the presence of all TCs,
with DOX exhibiting the best repressible profile. Error bars are SEM, n=2.
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FIGURE 2.8. EGFP expression by vIRG is completely repressed in the presence of
DOX. BS-C-1 cells were infected at an MOI of 1 with WR orr vIRG in the absence ((
DOX) or presence (+ DOX) of 100 ng/ml DOX, and 2 DPI cells were imaged by
fluorescence microscopy and EGFP expression was quantified
quantified. EGFP expression by
vIRG in the presence of DOX was repressed to levels comparable to WR. Error bars are
SEM, n=3.
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FIGURE 2.9. Repressible dose response to increasing concentrations of DOX. BSC-1 cells were infected at an MOI of 1 with WR or vIRG in the absence or presence of
increasing concentrations of DOX, and 2 DPI cells were imaged by fluorescence
luorescence
microscopy and EGFP expression was quantified
quantified. Error bars are SEM, n=3.

52

immer-like modulation of EGFP expression in vIRG as determined
FIGURE 2.10. Dimmer
by fluorescence microscopy
microscopy. BS-C-1 cells were infected at an MOI of 1 with vIRG in
the absence or presence of varying concentrations of DOX or IPTG, and 2 DPI cells were
imaged by fluorescence microscopy
microscopy. EGFP expression levels vary from levels
comparable to a negative control virus (WR) in the presence of DOX to levels
comparable to a positive control virus (vRGc) in the presence of IPTG.
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FIGURE 2.11. Dimmer--like modulation of EGFP expression in vIRG as determined
by flow cytometry. HeLa S3 cells were infected
fected at an MOI of 1 with vIRG, WR, or
vRGc in the absence or presence of varying concentrations of DOX or IPTG. Cells were
analyzed by flow cytometry (histograms in upper panel) and mean fluorescence values
were determined (lower panel). EGFP expressio
expression
n by vIRG can be modulated much like a
dimmer. Error bars are SEM, n=3.
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rheostat-like modulation of EGFP expression with IPTG and
FIGURE 2.12. Double rheostat
DOX. BS-C-1 cells were infected with vIRG in the absence or presence of varying
concentrations of DOX or IPTG
IPTG, and 2 DPI cells were imaged by fluorescence
luorescence
microscopy. The resulting single plaques display a wide range of EGFP expression
levels, allowing both inducers to simultan
simultaneously
eously modulate EGFP expression.
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vIRG. BS-C-1 cells were infected at
FIGURE 2.13. Kinetics of EGFP induction by vIRG
an MOI of 1 with vIRG, WR, or vRGc and treated with 1 mM IPTG at the time points
shown (+ IPTG) or left untreated. At various time points cells were imaged by
fluorescence microscopy and EGFP expression was quantified
quantified. Fluorescence levels in
WR- and vRGc-infected
infected cells were not altered by addition of IPTG (data shown are only
in the absence of IPTG). EGFP expression by vIRG was not affected when IPTG was
added between 0 and 12 hr, but increased significantly when IPTG was added between 18
and 48 hr, demonstrating that induction can be regulated even after infection.
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vIRG. BS-C-1
1 cells were infected at
FIGURE 2.14. Kinetics of EGFP repression by vIRG
an MOI of 1 with vIRG, WR, or vRGc in the presence of 1 mM IPTG (except when
labeled medium only) and at the time points shown DOX was added to 100 ng/ml
(+ DOX). At various time points cells were imaged by fluorescence microscopy
micro
and
EGFP expression was quantified
quantified. Fluorescence levels in WR- and vRGc-infected
vRGc
cells
were not altered by addition of DOX (data shown are in the presence of medium only).
EGFP expression by vIRG was not affected when DOX was added between 0 and 12 hr,
but decreased significantly when DOX was added between 18 and 24 hr,, demonstrating
that repression can be regulated even after infection.
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FIGURE 2.15. Addition of tetO operators in different numbers and arrangements
does not seem to prevent leaky expression of LacI
LacI. BS-C-1 cells were infected with
the different viruses in the absence ((- IPTG) or presence (+ IPTG) of 5 mM IPTG, and
isolated plaques were imaged by fluorescence microscopy. The levels of EGFP
expressionn in the absence of IPTG did not differ between the different recombinant
VACVs, indicating that the number and arrangement of tetO operators tested were not
able to stop leaky expression of LacI.
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FIGURE 2.16. Schematic of the “gene circuit” mechanism underlying the control of
gene expression in vIRG. The constitutive expression of tetR provides a continuous
continu
supply of the TetR repressor protein
protein. In the absence of inducers (middle panel), lacI is
expressed at low levels and iinterferes with the expression of EGFP. In the presence of
TCs (top panel), lacI is expressed abundantly, repressing the expression of EGFP. In the
presence of IPTG (lower panel), LacI is unable to block EGFP transcription.
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CHAPTER 3:

DEVELOPMENT OF A REPRESSIBLE VACCINIA VIRUS
EXPRESSION SYSTEM ASSEMBLED WITH REVERSE TET
REPRESSOR MUTANTS AND OTHER ELEMENTS FROM THE
TET OPERON
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3.1. ABSTRACT
A number of recombinant vaccinia viruses (VACVs) that contain elements from
the tetracycline (tet) operon system of E. coli were developed to repress the expression of
a reporter gene, enhanced green fluorescent protein (EGFP), in the presence of tet operon
inducers. The recombinant VACVs constitutively expressed six mutant versions of the
tet repressor gene (tetR) shown to bind tet operators in the presence, but not absence of
inducers (reverse tetR genes). In the absence of tetracyclines (TCs), such as tetracycline
(TET), doxycycline (DOX), and anhydrotetracyline (ATC), EGFP was expressed under
the control of a VACV promoter containing a tet operator, albeit at different levels. In
the presence of TCs, all recombinants exhibited various degrees of repression of EGFP
expression, with increasing concentrations of TCs leading to EGFP repression in a dose
dependent manner. All recombinants were primarily responsive to DOX, followed by
ATC and TET. In the presence of DOX, EGFP expression levels were similar to a
negative control virus at concentrations as low as 10 ng/ml. In light of the renewed
interest for the use of VACV as vaccine and therapeutic cancer vectors, the repressible
VACV expression system developed here can be used to tightly regulate genes essential
for VACV replication, thus functioning as a built-in safety mechanism to conditionally
control viral replication.
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3.2. INTRODUCTION
Vaccinia virus (VACV) belongs to the family Poxviridae and has many unique
characteristics that have led to its widespread use as a vaccine and therapeutic vector
(Moss, 1991, Moss, 1996). In addition to its large size (200 nm × 250 nm), VACV has a
190 kb genome that encodes its own necessary transcription machinery and allows
transcription to occur completely within the host cell cytoplasm. As a viral vector,
VACV can carry at least 25 kb of heterologous DNA (Smith and Moss, 1983), and it can
elicit strong humoral and cell-mediated immune responses (Mackett et al., 1982). VACV
has become most notable for its use as the smallpox vaccine that eradicated smallpox
worldwide (Fenner et al., 1988, World Health Organization. Global Commission for the
Certification of Smallpox Eradication and World Health Organization, 1980). After this
great achievement, VACV became one of the most characterized viruses, allowing the
development of heterologous vaccines and cancer therapeutics.
The use of VACV as a replication competent virus is associated with severe
adverse events, and there is a growing segment of the population for which its use is
contraindicated (Cono et al., 2003, Lane and Goldstein, 2003). Those that are
immunosuppressed, have (or had) atopic dermatitis and other skin conditions, and those
with heart conditions fall within the contraindicated population. This is a significant
limitation and is problematic for various reasons. Amidst the fears of bioterrorism and
the re-emergence of variola virus or related pathogenic poxviruses (Dhawan et al., 2001,
Di Giulio and Eckburg, 2004, Nalca et al., 2005, Gottschalk and Preiser, 2005), the US
has established a stockpile of the smallpox vaccine (Monath et al., 2004, Greenberg et al.,
2005, Greenberg and Kennedy, 2008). The currently stockpiled vaccine (ACAM2000),
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passaged in cell culture, has improved sterility (Greenberg and Kennedy, 2008, Monath
et al., 2004) over the previously used smallpox vaccine (Dryvax), produced in the skin of
calves (Rotz et al., 2001). However, the adverse events associated with virus replication
are still a significant concern with ACAM2000. One way to address these safety
concerns is to develop replication incompetent VACVs, such as MVA (Modified
Vaccinia Ankara). MVA-BN or IMVAMUNE is a potential next-generation smallpox
vaccine that is currently on fast-track clinical trials (Kennedy and Greenberg, 2009).
However, MVA elicits lower immune responses after a single immunization (thus
requiring multiple doses to elicit immune responses comparable to Dryvax or
ACAM2000) and it is replication-defective, thus unable to produce the “take”, the only
known correlate of protection against smallpox.
Thus, there is a need for alternative approaches to increase the safety of VACV
while maintaining its immunogenicity and its ability to produce a take. One approach
that meets these criteria is to place a gene essential to viral replication under the control
of a repressible system, which could serve as a built-in safety system. In cases where
adverse events were to occur, transcription of a gene essential for viral replication could
be blocked upon administration of an inducer, thus stopping the replication of the virus
and most importantly, the progression of the adverse event.
In this study, elements from the tet operon of E. coli and reverse mutants of the
tetR (revtetR) gene were used to generate recombinant VACVs that repress the
expression of a reporter gene, enhanced green fluorescent protein (EGFP), in the presence
of tetracyclines (TCs).
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3.3. MATERIALS AND METHODS

Viruses and Cell Culture. African green monkey kidney (BS-C-1) and human (HeLa
S3) cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% TET tested fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA)
at 37°C in 5% CO2. A clone derived from the Western Reserve (WR) strain of VACV
(ATCC VR-2035) and all recombinant VACVs were propagated in BS-C-1 and HeLa S3
cells and titered by plaque assay in BS-C-1 cells.

Transfer Vectors. The construction of the vRG0 transfer vector is detailed in Figure 3.1.
Briefly, the NheI and XmaI fragment of pAT008, a designed synthetic plasmid (DNA2.0,
Menlo Park, CA) that contains the revtetR (L17G) gene (Scholz et al., 2004), was
subcloned into the same sites of pSMART11 (Weber et al., 2007). The resulting plasmid
(pAT013) contains the revtetR gene under the control of the synthetic early/late VACV
PE/L promoter, the DsRed gene under the control of the natural late VACV P11 promoter
(back-to-back with the PE/L) with a 19 bp tetO2 placed directly downstream from P11 and
upstream from the transcriptional start site, and the gpt-gus fusion gene under the control
of the synthetic VACV PSel promoter (Hammond et al., 1997), flanked by segments of the
VACV thymidine kinase (TK) gene (left, TKL and right, TKR), which allows for
homologous recombination with the VACV TK genomic region. The final transfer
vector pAT020 was generated by transferring the EGFP gene from pAT010 into the BglII
and BspEI sites of pAT013. A control transfer vector (pAT018) for the generation of a
recombinant VACV constitutively expressing EGFP under the P11 promoter (vRGc) was
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generated by transferring the revtetR gene into plasmid pSMART10 (Weber et al., 2007),
and by replacing the DsRed gene with the EGFP gene as described above. Additionally,
transfer vectors with different mutants of the revtetR gene (Table 3.1) were generated by
subcloning the mutant revtetR synthetic genes (DNA2.0) into the NheI and XmaI sites in
pAT020.

Generation of Recombinant VACVs. The recombinant VACVs vRG0, vRG1, vRG2,
vRG3, vRG4, vRG5 (Table 3.1), and vRGc (a positive control virus without tetO2, thus
constitutively expressing EGFP under the P11 promoter) were generated via standard
homologous recombination by transfection of the transfer vectors into BS-C-1 cell
monolayers infected with VACV strain WR (also used as the negative control) at a
multiplicity of infection (MOI) of 0.05 plaque-forming units (PFU)/cell. Recombinant
VACVs were plaque purified in selection medium (25 µg/ml mycophenolic acid, 250
µg/ml xanthine, 15 µg/ml hypoxanthine); plaques were visualized either with substrate 5bromo-4-chloro-3-indolyl-β-D-glucuronide (X-Gluc) or by selecting and collecting only
EGFP+ expressing plaques detected via fluorescence microscopy. The purity of the
recombinant VACVs (absence of parental virus) was confirmed by checking multiple
dilutions of stocks in selection-free media for the presence of non-fluorescent (EGFP-)
plaques. High titer stocks of each recombinant VACV were generated by infecting HeLa
S3 cells at an MOI of 0.1. Infected cells were harvested 3 days post-infection (DPI) by
centrifugation at 200 × g for 10 min. Cells were then lysed by freezing and thawing,
sonicated, and trypsinized. Finally, cell lysates were clarified to remove contaminating
cell debris by a second round of sonication and centrifugation at 200 × g for 5 min.
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Determination of EGFP Expression. BS-C-1 cell monolayers in multiwell culture
plates were infected with the VACVs (30 PFU or an MOI of 1) in the presence of
medium only or various concentrations of anhydrotetracycline (ATC; with or without
various concentrations of MgCl2, allowed to form a complex for 1 hr before use),
tetracycline (TET), or doxycycline (DOX). At 2 DPI, EGFP expression by isolated
plaques or infected cells were determined by quantitative fluorescence microscopy (as
described below). In certain instances, cell monolayers were washed with 1× phosphatebuffered saline (PBS) pH 7.2, resuspended in equal parts of 1× PBS and 2% neutral
buffered formalin (1% final concentration), and analyzed with a fluorescence plate reader
(as described below) within 24 hr.

Imaging and Image Quantification. Infected cells and plaques were imaged using an
inverted fluorescence microscope (Axio Observer D1, Carl Zeiss, Thornwood, NY) with
or without a green bandpass filter (XF100-2, Omega Optical, Brattleboro, VT). EGFP
expression levels were quantified with the AxioVision software, release 4.8.1 (Carl Zeiss).

Fluorescence Quantification with a Microplate Reader. The fluorescence readings of
infected cells were obtained with a fluorescence plate reader (Synergy HT Multi-Mode
Microplate Reader, BioTek Instruments, Winooski, VT) using a 485/20 nm excitation
and a 528/20 nm emission filter pair. EGFP expression levels are quantified with the
KC4 v3.4 software (BioTek Instruments).
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3.4. RESULTS

vRG0 Expresses EGFP at High Levels in the Absence of TCs. The first mutant
revtetR tested in this system was based on a tetR mutant with a single amino acid change
at position 17 that changes leucine to glycine (L17G) (Scholz et al., 2004). Although this
L17G revTetR mutant was characterized in bacteria (E. coli), it was appealing to test
initially in this system, since a single mutation is less likely to alter other important
regions on the repressor protein. In addition, this mutant was characterized as a single
domain protein, unlike most other revtetR mutants that were characterized as fusion
proteins with the VP16 transcriptional activator from herpes simplex virus. Moreover, it
is important to note that ATC (a TC-derivative) was used to characterize the L17G
mutant in E. coli.
In the absence of TCs, BS-C-1 cells infected with vRG0, a positive control virus
(vRGc) or a negative control virus (WR) displayed the expected cytopathic effect (CPE)
2 DPI when observed under brightfield microscopy. Additionally, vRG0 and vRGc
plaques displayed similar high levels of EGFP expression under fluorescence microscopy,
while WR-infected cells did not (Figure 3.2).

EGFP Expression Levels by vRG0 were not Repressed even in the Presence of High
Concentrations of TCs. To test whether vRG0 was repressible by TCs, BS-C-1 cells
were infected with vRG0 in the presence of increasing concentrations of ATC, TET, or
DOX. The CPE observed by brightfield microscopy 2 DPI was indistinguishable from
the CPE observed from cells treated with ATC and 10 µg/ml or less of TET or DOX
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(Figure 3.3). However, cells infected in the presence of 100 µg/ml of TET or DOX
exhibited morphology associated with cell toxicity, and as a result the plaques were
smaller in comparison to infected cells treated with lower concentrations of TET or DOX.
Cells infected in the presence of ATC did not incur any toxicity because lower
concentrations were used in comparison to the TET and DOX, as ATC has the highest
affinity for revTetR (Scholz et al., 2004). Increasing concentrations of TCs did not
decrease EGFP expression in vRG0 plaques when observed by fluorescence microscopy.
In the presence of 100 µg/ml of TET or DOX, infected cells exhibited lower EGFP
expression, probably due to cell toxicity.
Since TCs complexed to MgCl2 bind to the TetR repressor with higher affinity
than TCs alone (a commonly used strategy when studying induced conformation of the
repressor by x-ray crystallography), we decided to incubate ATC with MgCl2 to allow for
complex formation (Kamionka et al., 2004, Scholz et al., 2003). Cells infected with
vRG0 in the presence of varying concentrations of ATC-MgCl2 displayed typical CPE 2
DPI at 20 mM or below of MgCl2, while at the highest concentration of MgCl2 (100 mM
MgCl2), the cells exhibited toxicity-associated morphology (data not shown). When
plaques were observed by fluorescence microscopy, there was no EGFP repression in the
presence of increasing concentrations of the ATC-MgCl2 complex (Figure 3.4). In
addition, at the highest concentrations of ATC-MgCl2 complex tested (100 mM), no
fluorescent plaques were observed, probably as a result of MgCl2 cell toxicity. Thus, we
concluded that that vRG0 was not repressible and decided to test new revtetR mutants
(Table 3.1).
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RevTetR mutants Lead to Different EGFP Expression Levels in the Absence of TCs.
Five new recombinant VACVs (vRG1, vRG2, vRG3, vRG4, and vRG5) were generated
(Table 3.1), each expressing a different mutant tetR gene previously shown to display the
reverse phenotype in eukaryotic systems when fused to a VP16 domain from herpes
simplex virus that induces gene expression. Since the transactivator will not function in
VACV, as VACV relies on its own specialized transcription machinery, we tested the
revTetR mutants without the VP16 transactivator. Additionally, these mutants were
initially characterized with the TC derivative, DOX; TET and DOX between 0.1 to 1
µg/ml was successfully used in TC-inducible VACV expression systems (Trakman et al.,
2000, Weber et al. 2007). Furthermore, DOX is an FDA approved, broad-spectrum drug
that exhibits antimicrobial and off target activities (Greenwald et al., 2001)
In the absence of TCs, BS-C-1 cells infected with the VACVs displayed the
expected CPE 2 DPI under brightfield microscopy. When observed under fluorescence
microscopy, vRG5, vRG0, and vRGc plaques displayed similar high levels of EGFP
expression (Figure 3.5). The other recombinants had varying lower levels of expression,
with vRG3 and vRG4 having equal levels of EGFP expression, vRG2 less, and vRG1
least.

RevTetR mutants Lead to Different Repression of EGFP Expression Levels in the
Presence of TCs. BS-C-1 cells were infected with the different VACVs at an MOI of 1
in the absence or presence of varying concentrations of TCs. Two DPI cells were imaged
by brightfield and fluorescence microscopy and EGFP expression was subsequently
quantified. Based on fluorescence microscopy images (Figure 3.6) and quantification
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(Figures 3.7, 3.8, and 3.9), all revTetR mutants displayed varying levels of EGFP
repression, generally being most sensitive to DOX, followed by ATC and then TET.
vRG0 was repressible, but EGFP expression remained high even at the highest
concentrations of TCs tested. In the presence of DOX, only vRG1 and vRG2 fully
repressed EGFP expression to the levels of the negative control WR at 0.1 µg/ml,
although EGFP expression levels by vRG1 in the absence of TCs were the lowest (Figure
3.9). In addition, vRG4 was able to be fully repressed at 1 µg/ml of DOX, while vRG3
was fully repressed at 10 µg/ml of DOX. In the absence of TCs, vRG5 was able to
express EGFP at the same level as vRGc, although it was not able to become fully
repressed based on fluorescence imaging quantification.

Fluorescence Multiwell Reader Displays Higher Sensitivity at Low Levels of EGFP
Expression. To potentially increase the sensitivity and reproducibility of the
fluorescence quantification and to better ascertain the repressible systems that exhibit full
repression, a fluorescence plate reader (fluorometer) was employed. BS-C-1 cells were
infected with the VACVs at an MOI of 1 in multiwell plates in the absence or presence of
increasing concentrations of TCs, and 2 DPI cells were fixed and read on the multiwell
fluorescence reader (Figure 3.10, 3.11, and 3.12). The results follow essentially the same
trends observed by fluorescence imaging. In addition, it seems that lower levels of EGFP
expression were detected with increased sensitivity, although there was more variance at
higher levels of EGFP expression. Thus, for the purposes of determining EGFP
repression by the recombinant VACVs, the fluorometer seems more appropriate as it is
more sensitive at lower levels of expression.
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Full Repression of EGFP Expression is Achievable in VACV. To determine the TC
concentration that fully represses EGFP expression, BS-C-1 cells were infected with the
VACVs in the absence or presence of increasing concentrations of TCs, and 2 DPI cells
were fixed and read on the fluorescence multiwell reader. In the presence of increasing
concentrations of ATC (0.1 ng/ml – 1,000 ng/ml), vRG1-vRG5 showed a repressible
dose response (Figure 3.13). vRG1 was fully repressed to the levels of the negative
control WR in the presence of 100 ng/ml ATC, while vRG2, vRG3, and vRG4 were fully
repressed in the presence of 1,000 ng/ml ATC. Only vRG5 and vRG0 were not fully
repressed at 1,000 ng/ml of ATC.
In the presence of increasing concentrations of TET (1 ng/ml – 10,000 ng/ml), the
expression in vRG1-vRG5 also showed a repressible dose response (Fig. 3.14). However,
vRG1 was the only recombinant that became fully repressed to the levels of WR. In the
presence of increasing concentrations of DOX (1 ng/ml – 10,000 ng/ml), all recombinant
VACVs show a repressible dose response (Figure 3.15). With the exception of vRG0 and
vRG5, all other recombinants were fully repressed by concentrations of DOX within the
range tested; however, some recombinant VACVs are more sensitive to DOX than others.
vRG1 was fully repressed at 10 ng/ml of DOX, vRG2 was next at 100 ng/ml, and vRG3
and vRG4 were next at 1,000 ng/ml. At the highest DOX concentration tested (10,000
ng/ml), vRG5 seems to be mostly, but not completely repressed.
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3.5. DISCUSSION AND CONCLUSIONS
All of the revTetR repressor mutants tested in this VACV expression system
displayed a repressible phenotype in the presence of TCs, albeit with unique phenotypes.
For example, vRG0 (with the single L17G tetR mutant) was only marginally repressible,
while the recombinant VACV most sensitive to TCs (vRG1) was also the one with the
lowest level of EGFP expression in the absence of TCs. As a general trend, the higher
the level of EGFP expression in the absence of TCs, the higher the TC concentration
needed to completely repress the system.
An aspect that can be tested with this repressible system is whether EGFP
expression can be repressed even after infection. As it was demonstrated in Chapter 2 in
a modulatory expression system that is both repressible and inducible, EGFP expression
could be stopped in the presence of DOX at various time points post-infection (Titong
and Verardi, unpublished data). Similar experiments could demonstrate if this is true in
this revTetR based repression system.
Another interesting aspect of this work is the sensitivity of fluorescence
quantification. In this repressible system, the main goal is to establish levels of
repression, in particular how close EGFP expression levels are to negative control levels.
The use of quantitative fluorescence imaging was reliable for the measurement of high
fluorescence levels, but the multiwell fluorometer was considerably more sensitive for
measurements of low levels of fluorescence, despite having greater variation in the higher
ranges of expression.
There are many applications for which the different revTetR versions in these
repressible systems can be used. In some cases, genes may not necessarily have to be
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expressed at high levels to achieve the necessary phenotype. In general, enzymes are an
example of a class of genes do not need high levels of expression, in which case the
vRG1 or vRG2 systems could be appropriate to use. In other cases, such as for the
expression of virion structural proteins, higher levels of expression may be needed and
vRG3, vRG4, or vRG5 may be more applicable as each exhibits increasing levels of
expression in the absence of TCs.
Increasing the safety profile of VACV vectors can be used for the development of
the next-generation smallpox vaccines, human and animal VACV-vectored vaccines, as
well as immune and oncolytic therapies. More specifically, a new generation of
smallpox vaccine can be generated by placing a gene essential for viral replication under
the control of a repressible system. This next-generation smallpox vaccine would not be
inferior to previous vaccines as it would replicate in the absence of TCs and it would be
functionally identical to Dryvax or ACAM2000 and produce the only established
correlate of protection (the take). Importantly, this new vaccine would have an enhanced
safety profile as this built-in safety mechanism could stop viral replication after
administration of FDA approved TCs (such as DOX) in the event of adverse reactions to
vaccination.
Another example in which a repressible system would be extremely useful is the
current Raboral V-RG (Merial, Duluth, GA) sylvatic rabies vaccine, a VACV-vectored
vaccine expressing the glycoprotein of rabies that is widely used to control sylvatic rabies
(Pastoret and Brochier, 1996, Brochier et al., 1996). The means in which this vaccine is
delivered poses great risks, especially to those with contraindications against vaccination
with VACV. Vaccine baits are dropped in wooded areas, in some cases these areas are
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very near urbanized settings (Reynolds et al., 2007). Thus, humans have the potential to
be exposed to the live vaccine (Centers for Disease Control and Prevention (CDC), 2009).
By using our built-in safety repressible mechanism, a newer generation of recombinant
rabies vaccines could be developed. Should a contraindicated individual accidentally
come into contact with vaccine baits, any adverse events due to VACV infection could be
stopped with the administration of TCs.
VACV on its own has an array of practical applications and has led to great
achievements in medicine. We have successfully described an unique repressible system
that can be built into VACV and used to greatly improve its safety profile as a viral
vector for vaccines and immunotherapeutics.
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3.6. FIGURES AND TABLE

NheI

XmaI

revtetR

pAT008
BglII

BspEI
TKL

gus

gpt PSe/ l

DsRed

NheI
P11

tetO2

PE/ L

XmaI

tetR

TKR

pSMART11
BspEI
TKL

gus

gpt PSe/ l

BglII
DsRed

tetO2

P11

PE/ L

revtetR

TKR

pAT013
BamHI

BspEI

EGFP

pAT010
Final Transfer Vector (pAT020)
TKL

gus

gpt PSe/l

EGFP

tetO2

P11 PE/L

revtetR

TKR

FIGURE 3.1. Construction of the transfer vector pAT015 for the generation of
vRG0. The cloning steps leading to the generation of the final transfer vector are shown.
pAT020 contains the gpt-gus fusion gene under the control of a synthetic early/late
VACV promoter (PSel), the EGFP gene under the control of an engineered late P11
promoter with a tetO2 sequence located directly downstream, the revtetR gene under the
control of a constitutive strong synthetic early/late promoter (PE/L), all flanked by TKL
and TKR sequences that direct recombination with the TK gene of VACV.
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FIGURE 3.2. vRG0 expresses EGFP at high levels in the absence of TCs.
TCs BS-C-1
cells infected with WR, vRGc, or vRG0 in the absence of TCs displayed typical CPE 2
DPI, and single isolated plaques were imaged by brightfield and fluorescence microscopy.
Plaques from vRG0 and vRGc (positive control virus) displayed similar high
hig levels of
EGFP expression, while WR (negative control virus) did not.

78

FIGURE 3.3. EGFP expression levels by vRG0 were not repressed in the presence
of TCs. BS-C-1 cells infected with vRG0 in the presence of TCs displayed typical CPE
2 DPI in all concentrations of ATC or 10 µg/ml or less of TET or DOX. However, cells
infected with 100 µg/ml of TET or DOX exhibited morphology associated with cell
toxicity and as a result the plaques were smaller. Increasing concentrations of TCs did
not decrease EGFP expression in vRG0 plaques when observed by fluorescence
microscopy.
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FIGURE 3.4. EGFP expression is not repressed in cells infected with vRG0 in the
presence of varying concentrations of the ATC-MgCl2 complex. BS-C-1 cells
infected with vRG0 in the presence of ATC-MgCl2 displayed typical CPE 2 DPI in
concentrations of 20 mM MgCl2 or less. However, cells infected with 100 mM of MgCl2
exhibited morphology associated with toxicity and as a result a normal infection did not
occur in comparison to lower concentrations (brightfield images not shown). Regardless,
EGFP expression by vRG0 was not repressed by ATC-MgCl2.
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FIGURE 3.5. RevTetR mutants lead to different EGFP expression levels in the
absence of TCs. BS-C-1 cells infected with the VACVs in the absence of TCs displayed
typical CPE 2 DPI, and single isolated plaques were imaged by brightfield and
fluorescence microscopy. vRG5, vRG0 and vRGc plaques displayed similar high
fluorescence levels. The other recombinants exhibited decreasing levels of EGFP
expression in the following order, vRG3 and vRG4 were equal followed by vRG2 and
then by vRG1.
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FIGURE 3.6. EGFP expression is repressed in the presence of increasing
concentrations of TCs. BS-C-1 cells were infected at an MOI of 1 with the VACVs in
the absence or presence of TCs and imaged by fluorescence microscopy 2 DPI. With the
exception of vRG0, EGFP expression was repressed in all other recombinant VACVs,
although not all expressed EGFP at high levels in the presence of TCs.
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FIGURE 3.7. EGFP expression is repressed in the presence of increasing
concentrations of ATC when measured by fluorescence imaging quantification.
Fluorescence levels of cells previously imaged (Figure 3.6) were quantified. Cells
infected with vRG1 to vRG5 show repression of EGFP expression with increasing
concentrations of ATC. vRG0 displayed minimal repression even at the highest
concentration of ATC tested. Error bars are SEM, n=3.
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FIGURE 3.8. EGFP expression is repressed in the presence of increasing
concentrations of TET when measured by fluorescence imaging quantification.
Fluorescence levels of cells previously imaged (Figure 3.6) were quantified. Cells
infected with vRG1 to vRG5 show repression of EGFP expression with increasing
concentrations of TET. vRG0 displayed minimal repression even at the highest
concentration of TET tested. Error bars are SEM, n=3.
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FIGURE 3.9. EGFP expression is repressed in the presence of increasing
concentrations of DOX when measured by fluorescence imaging quantification.
Fluorescence levels of cells previously imaged (Figure 3.6) were quantified. Cells
infected with vRG1 to vRG5 show repression of EGFP expression with increasing
concentrations of DOX. Expression by vRG1, vRG2, vRG3, and vRG4 is repressible to
the levels of the negative control WR. vRG0 displayed minimal repression even at the
highest concentration of DOX tested. Error bars are SEM, n=3.
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FIGURE 3.10. EGFP expression is repressed in the presence of increasing
concentrations of ATC when measured by a multiwell fluorescence reader. In this
preliminary study, BS-C-1 cells were infected at an MOI of 1 with the VACVs in the
absence or presence of ATC and 2 DPI cells were fixed and quantified with a fluorometer.
EGFP expression levels were repressed in the presence of increasing concentrations of
ATC. Error bars are SEM, n=2.
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FIGURE 3.11. EGFP expression is repressed in the presence of increasing
concentrations of TET when measured by a multiwell fluorescence reader. In this
preliminary study, BS-C-1 cells were infected at an MOI of 1 with the VACVs in the
absence or presence of TET and 2 DPI cells were fixed and quantified with a fluorometer.
EGFP expression levels were repressed in the presence of increasing concentrations of
TET. Error bars are SEM, n=2.

95

96

FIGURE 3.12. EGFP expression is repressed in the presence of increasing
concentrations of DOX when measured by a multiwell fluorescence reader. In this
preliminary study, BS-C-1 cells were infected at an MOI of 1 with the VACVs in the
absence or presence of DOX and 2 DPI cells were fixed and quantified with a
fluorometer. EGFP expression levels were repressed in the presence of increasing
concentrations of DOX. Error bars are SEM, n=2.
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FIGURE 3.13. ATC represses EGFP expression in a dose response manner. BS-C-1
cells were infected at an MOI of 1 with the VACVs in the absence or presence of ATC
and 2 DPI cells were fixed and quantified with a multiwell fluorescence reader. EGFP
expression levels were repressed in the presence of increasing concentrations of ATC.
Error bars are SEM, n=2.
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FIGURE 3.14. TET represses EGFP expression in a dose response manner. BS-C-1
cells were infected at an MOI of 1 with the VACVs in the absence or presence of TET
and 2 DPI cells were fixed and quantified with a multiwell fluorescence reader. EGFP
expression levels were repressed in the presence of increasing concentrations of TET.
Error bars are SEM, n=2.
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FIGURE 3.15. DOX represses EGFP expression in a dose response manner. BS-C1 cells were infected at an MOI of 1 with the VACVs in the absence or presence of DOX
and 2 DPI cells were fixed and quantified with a multiwell fluorescence reader. EGFP
expression levels were repressed in the presence of increasing concentrations of DOX.
Error bars are SEM, n=2.
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TABLE 3.1. RevTetR mutants used to generate the recombinant VACVs used in
this study.
Recombinant

VACV

revTetR

Mutations

References

L17G

Scholz et al., 2004

E71K, D95N, L101S, G102D

Gossen et al., 1995

S12G, E19G, A56P, D148E, H179R

Urlinger et al., 2000

rtTA-S2

E19G, A56P, D148E, H179R

Urlinger et al., 2000

vRG4

rtTA-M1

S12G, E19G, A56P

Urlinger et al., 2000

vRG5

rtTA-19/56R

E19G, A56P

Urlinger et al., 2000

vRG0

L17G

vRG1

Original rtTA

vRG2

Advanced rtTA
(rtTA-M2)

vRG3

!
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